PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
23053255-1	2012	PURPOSE: Dinaciclib, a selective inhibitor of cyclin-dependent kinase (CDK) 1, CDK2, CDK5, and CDK9, is metabolized via CYP3A4.	dinaciclib	9-19	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	120-126	
35053380-10	2022	As well-known CDK inhibitors, dinaciclib and kenpaullone stabilize PXR and result in elevated expression and activity of PXR-targeted DMETs, including carboxylesterases, CYP3A4 and P-gp.	dinaciclib	30-40	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	170-176	
31676845-6	2019	In this study, we show that dinaciclib, a potent cyclin dependent kinase inhibitor, significantly increases the basal CYP3A4 and PXR levels in 24 hours.	dinaciclib	28-38	cytochrome P450 family 3 subfamily A member 4	Homo sapiens	118-124